SCHEMBL178752

SCHEMBL178752

COC(=O)[C@@H](Cc1cc(C)c2[nH]ncc2c1)NC(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
ALOX15 P16050 1/20 0.49
ACACB O00763 1/20 0.48
CTSL P07711 2/20 0.46
CTSB P07858 2/20 0.46
CTSS P25774 2/20 0.46
KYNU Q16719 1/20 0.46
CALCA P06881 3/20 0.46
NOS1 P29475 1/20 0.45
CTSK P43235 1/20 0.45
CYP3A4 P08684 3/20 0.45
TSHR P16473 3/20 0.45
TYR P14679 1/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23564698 1.00 ALDH1A1 (0.49) ALDH1A1ALOX15ACACBCTSLCTSB
SCHEMBL31628221 1.00 ALDH1A1 (0.49) ALDH1A1ALOX15ACACBCTSLCTSB
SCHEMBL13030965 0.93 CTSL (0.47) ALDH1A1ALOX15ACACBCTSLCTSB
SCHEMBL30799347 0.93 CTSL (0.47) ALDH1A1ALOX15ACACBCTSLCTSB
SCHEMBL29182147 0.93 CTSL (0.47) ALDH1A1ALOX15ACACBCTSLCTSB
SCHEMBL31180141 0.88 CALCA (0.46) CALCA
SCHEMBL31180191 0.88 CALCA (0.46) CALCA
SCHEMBL4500163 0.86 CTSL (0.50) CTSLCTSBCTSSCTSKMAPT
SCHEMBL4508424 0.85 CALCRL (0.44) ACACBCTSLCTSBCTSSCALCA
SCHEMBL137686 0.85 ACACB (0.48) ACACBCALCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220401439-A1 INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS PFIZER IRELAND PHARMACEUTICALS (IE) 2022-12-22 US disclosed
EP-3863629-A1 PRODRUGS OF CGRP ANTAGONISTS Biohaven Pharmaceutical Holding Company Ltd. (US) 2021-08-18 EP disclosed
EP-2552906-B1 CGRP RECEPTOR ANTAGONIST BRISTOL MYERS SQUIBB CO (US) 2016-01-06 EP disclosed
US-8481546-B2 CGRP receptor antagonist BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-09 US disclosed
US-20120059017-A1 CGRP Receptor Antagonist BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
WO-2011123232-A1 CGRP RECEPTOR ANTAGONIST BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-06 WO disclosed
US-7569578-B2 Heterocyclic anti-migraine agents BRISTOL-MEYERS SQUIBB COMPANY (US) 2009-08-04 US disclosed
US-7449586-B2 Processes for the preparation of CGRP-receptor antagonists and intermediates thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-11 US disclosed
US-7449586-B2 Processes for the preparation of CGRP-receptor antagonists and intermediates thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401439-A1 INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS CALCA, CALCB, CALCRL ALDH1A1 2986/4885ALOX15 1564/4885ACACB 3361/4885
US-20120059017-A1 CGRP Receptor Antagonist CALCRL, PTGIR, CALCR ALDH1A1 1718/4885ALOX15 763/4885ACACB 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.